The aim of this study was to determine the effect of butaphosphan and cyanocobalamin (BTPC) supplementation on plasma metabolites and milk production in postpartum dairy cows. A total of fifty-two Holstein cows were randomly assigned to receive either: (1) 10 ml of saline (NaCl 0.9%, control group); (2) 1000 mg of butaphosphan and 0.5 mg of cyanocobalamin (BTPC1 group); and (3) 2000 mg of butaphosphan and 1.0 mg of cyanocobalamin (BTPC2 group). All cows received injections every 5 days from calving to 20 days in milk (DIM). Blood samples were collected every 15 days from calving until 75 DIM to determine serum concentration of glucose, non-esterified fatty acids (NEFA), b-hydroxybutyrate (BHB), cholesterol, urea, calcium (Ca), phosphorus (P), magnesium (Mg), aminotransferase aspartate (AST) and g-glutamyltransferase (GGT). The body condition score (BCS) and milk production were evaluated from calving until 90 DIM. Increasing doses of BTPC caused a linear reduction in plasma concentrations of NEFA and cholesterol. Supplementation of BTPC also reduced concentrations of BHB but it did not differ between the two treatment doses. Milk yield and milk protein had a linear increase with increasing doses of BTPC. A quadratic effect was detected for milk fat and total milk solids according to treatment dose, and BTPC1 had the lowest mean values. Concentrations of glucose, urea, P, Mg, AST, GGT, milk lactose and BCS were not affected by treatment. These results indicate that injections of BTPC during the early postpartum period can reduce NEFA and BHB concentrations and increase milk production in Holstein cows.Keywords: butaphosphan, cyanocobalamin, postpartum dairy cows, non-esterified fatty acid
ImplicationsThis study presents a new metaphylactic strategy aimed to reduce the intensity of negative energy balance (NEB) in postpartum dairy cows. Unlike previous studies, the current protocol consists of five injections of cyanocobalamin and butaphosphan at 5 days interval during the first 20 days in milk (DIM), the period of greatest metabolic challenge for dairy cows. The results of this experiment indicate that this protocol can improve metabolic adaptation in the early postpartum period, by reducing adipose tissue mobilization and increasing milk production.
The aim of study was to evaluate whether butafosfan, associated or not with cyanocobalamin, alters the metabolic profile, hemogasometrics and acute phase proteins in recent postpartum dairy cows. Twenty-five cows (n ¼ 25) were selected for study and divided into three groups: Butafosfan (BUT, n ¼ 9); Butafosfan þ Cyanocobalamin (BUTC, n ¼ 9); and Control (CTL, n ¼ 7). Treatments were applied daily from calving until 5 days postpartum. Blood samples for hemogasometry were performed on days 0, 1, 2 and 3, and for other metabolites on days 0, 1, 2, 3, 4, 5, 10, 15, 20 and 28 postpartum. Blood pH was lower in the BUT and BUTC groups than in the CTL group (p ¼ .03) and carbon dioxide pressure was higher in the BUT and BUTC groups compared to CTL (p ¼ .01). In addition, ionised calcium levels were higher in the BUT and BUTC groups (p ¼ .0003) in comparison to CTL, whereas the BUT group had higher levels. The BUT group had the lowest levels of paraoxonase (p ¼ .03). On the other hand, glucose levels tended to be highest in the BUT group (p ¼ .08). The butafosfan with or without cyanocobalamin increased ionised calcium levels and tended to stabilise blood pH in the early post-partum cows, and butafosfan without cyanocobalamin tended to increase blood glucose levels. HIGHLIGHTS Treated animals increase serum ionised calcium; Treated animals have a reduction in blood pH; Butafosfan tends to increase the glucose concentration.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.